Pre-clinical studies, involving co-culture of tumor cells and peripheral blood mononuclear cells, show that combined EGFR-TKI and anti-PD-1 antibody therapies do not produce synergistic tumor cell killing effects (42). Here, PDCD1 is linked to neoplasm.